SG11201407345QA - Pyrazole compounds as sglt1 inhibitors - Google Patents

Pyrazole compounds as sglt1 inhibitors

Info

Publication number
SG11201407345QA
SG11201407345QA SG11201407345QA SG11201407345QA SG11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA SG 11201407345Q A SG11201407345Q A SG 11201407345QA
Authority
SG
Singapore
Prior art keywords
lllll
international
indiana
indianapolis
iii
Prior art date
Application number
SG11201407345QA
Other languages
English (en)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407345Q(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201407345QA publication Critical patent/SG11201407345QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201407345QA 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors SG11201407345QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26
PCT/US2013/039164 WO2013169546A1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Publications (1)

Publication Number Publication Date
SG11201407345QA true SG11201407345QA (en) 2014-12-30

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407345QA SG11201407345QA (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Country Status (43)

Country Link
US (2) US8697849B2 (is)
EP (1) EP2850084B1 (is)
JP (1) JP6148725B2 (is)
KR (1) KR101685779B1 (is)
AP (1) AP3593A (is)
AR (1) AR090806A1 (is)
AU (1) AU2013259946B2 (is)
BR (1) BR112014026198B1 (is)
CA (1) CA2869323C (is)
CL (1) CL2014002845A1 (is)
CO (1) CO7141429A2 (is)
CR (1) CR20140473A (is)
CY (1) CY1117912T1 (is)
DK (1) DK2850084T3 (is)
DO (1) DOP2014000250A (is)
EA (1) EA024207B1 (is)
EC (1) ECSP14026088A (is)
ES (1) ES2588835T3 (is)
GT (1) GT201400242A (is)
HK (1) HK1202542A1 (is)
HR (1) HRP20160804T1 (is)
HU (1) HUE030414T2 (is)
IL (1) IL235427A (is)
IN (1) IN2014DN07996A (is)
JO (1) JO3136B1 (is)
LT (1) LT2850084T (is)
MA (1) MA37501B1 (is)
ME (1) ME02405B (is)
MX (1) MX357058B (is)
MY (1) MY177326A (is)
NZ (1) NZ700356A (is)
PE (1) PE20142399A1 (is)
PH (1) PH12014502492B1 (is)
PL (1) PL2850084T3 (is)
PT (1) PT2850084T (is)
RS (1) RS55107B1 (is)
SG (1) SG11201407345QA (is)
SI (1) SI2850084T1 (is)
TN (1) TN2014000410A1 (is)
TW (1) TWI579295B (is)
UA (1) UA113086C2 (is)
WO (1) WO2013169546A1 (is)
ZA (1) ZA201407531B (is)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AR097890A1 (es) 2013-10-17 2016-04-20 Lilly Co Eli Compuestos de urea
JO3298B1 (ar) 2013-11-01 2018-09-16 Lilly Co Eli مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
CN111902408B (zh) 2018-04-04 2023-11-14 日本烟草产业株式会社 杂芳基取代的吡唑化合物及其药物用途
KR20220056219A (ko) * 2019-09-04 2022-05-04 니뽄 다바코 산교 가부시키가이샤 병용 의약에 의한 당뇨병의 치료 또는 예방 방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001016147A1 (fr) 1999-08-31 2001-03-08 Kissei Pharmaceutical Co., Ltd. Derives de glucopyranosyloxypyrazole, compositions medicinales renfermant lesdits derives et produits intermediaires obtenus au cours de leur production
WO2002068439A1 (fr) 2001-02-26 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
NZ538117A (en) * 2002-08-08 2007-01-26 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7973012B2 (en) * 2006-05-19 2011-07-05 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound
AU2008344436B2 (en) 2007-12-27 2013-08-29 Kissei Pharmaceutical Co., Ltd. Monosebacate of pyrazole derivative
KR101653853B1 (ko) 2009-02-23 2016-09-02 다이쇼 세이야꾸 가부시끼가이샤 Sglt1 저해제로서의 4-이소프로필페닐 글루시톨 화합물
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 sglt-1/sglt-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
GT201400242A (es) 2015-08-27
CO7141429A2 (es) 2014-12-12
PH12014502492A1 (en) 2015-01-12
KR20150001798A (ko) 2015-01-06
CR20140473A (es) 2014-11-21
CL2014002845A1 (es) 2015-01-30
US8697849B2 (en) 2014-04-15
NZ700356A (en) 2016-06-24
CY1117912T1 (el) 2017-05-17
CN104284894A (zh) 2015-01-14
AR090806A1 (es) 2014-12-10
ECSP14026088A (es) 2015-09-30
IL235427A (en) 2016-06-30
TW201406773A (zh) 2014-02-16
US20140162967A1 (en) 2014-06-12
IN2014DN07996A (is) 2015-05-01
JO3136B1 (ar) 2017-09-20
EA201491852A1 (ru) 2015-02-27
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
ME02405B (me) 2016-09-20
CA2869323C (en) 2016-03-29
LT2850084T (lt) 2016-09-12
AU2013259946A1 (en) 2014-10-16
SI2850084T1 (sl) 2016-07-29
JP2015516419A (ja) 2015-06-11
DOP2014000250A (es) 2014-11-30
HRP20160804T1 (hr) 2016-08-12
CN104284894B (zh) 2016-02-17
BR112014026198A2 (pt) 2017-06-27
EP2850084A1 (en) 2015-03-25
CA2869323A1 (en) 2013-11-14
AP2014008044A0 (en) 2014-11-30
AP3593A (en) 2016-02-15
DK2850084T3 (en) 2016-09-12
HUE030414T2 (en) 2017-05-29
ES2588835T3 (es) 2016-11-07
PT2850084T (pt) 2016-08-02
EA024207B1 (ru) 2016-08-31
ZA201407531B (en) 2016-05-25
MY177326A (en) 2020-09-11
JP6148725B2 (ja) 2017-06-14
PL2850084T3 (pl) 2017-05-31
TN2014000410A1 (en) 2015-12-21
US9296775B2 (en) 2016-03-29
MA37501B1 (fr) 2016-11-30
US20130303471A1 (en) 2013-11-14
EP2850084B1 (en) 2016-06-15
AU2013259946B2 (en) 2015-09-10
PE20142399A1 (es) 2015-01-22
PH12014502492B1 (en) 2015-01-12
HK1202542A1 (zh) 2015-10-02
WO2013169546A1 (en) 2013-11-14
RS55107B1 (sr) 2016-12-30
TWI579295B (zh) 2017-04-21
MX2014013615A (es) 2015-02-12
BR112014026198B1 (pt) 2021-02-02
MX357058B (es) 2018-06-25
MA37501A1 (fr) 2016-03-31

Similar Documents

Publication Publication Date Title
SG11201407345QA (en) Pyrazole compounds as sglt1 inhibitors
SG11201408095XA (en) Fibroblast growth factor 21 proteins
SG11201408641UA (en) Phenoxyethyl piperidine compounds
SG11201408629QA (en) Dimethyl-benzoic acid compounds
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201407655TA (en) Therapeutic uses of fibroblast growth factor 21 proteins
SG11201906763RA (en) Pyrrolo [1,2-b] pyridazine derivatives
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201909022PA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201408094YA (en) Neprilysin inhibitors
SG11201907032RA (en) Amino pyrimidine compounds useful as ssao inhibitors
SG11201408261UA (en) Syringe
SG11201803627XA (en) N-substituted indole derivatives as pge2 receptor modulators
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201408271VA (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201407533SA (en) Antiviral compounds
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201810177VA (en) Pet-imaging immunomodulators
SG11201810371XA (en) ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
SG11201407189XA (en) C-17 bicyclic amines of triterpenoids with hiv maturation inhibitory activity
SG11201909680UA (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
SG11201808686VA (en) Synthesis of indazoles
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors